Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023
NEW YORK, April 16, 2023 – Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), today […]
Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline
Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly. Funding will support clinical development of Volastra’s […]
Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023
NEW YORK, April 16, 2023 – Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), today […]
Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline
Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly. Funding will support clinical development of Volastra’s […]
A closer look at Volastra’s lead program: KIF18A inhibitor
By Christina Eng, Ph.D., VP, Head of Biology Earlier this month at the FASEB Consequences of Aneuploidy conference, we shared […]
Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022
NEW YORK, September 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability to treat cancer, today […]
Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference
Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor models, with no effect on […]
Volastra Therapeutics Announces Participation in 2022 Guggenheim Synthetic Lethality Day
NEW YORK, May 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN) as a vulnerability […]